Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosidenib + durvalumab + gemcitabine/cisplatin for first-line IDH1-mutant cholangiocarcinoma
2024-514261-19-00Phase 2Authorised
- Sponsor
- Servier
- Start
- Mar 2025
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 2, open-label trial of ivosidenib, durvalumab, gemcitabine and cisplatin in cholangiocarcinoma (CCA) (2 arms), sponsored by Servier. Primary endpoints: Dose-limiting toxicities, Adverse events and 2 more. Planned start Mar 2025; status: authorised.
02
Drugs
ivosidenibdurvalumabgemcitabinecisplatin
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2024-514261-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514261-19-00.